Fig. 2From: PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitisNonworsening of fibrosis at Weeks 48 and 96 among noncirrhotic patients in the phase 2 simtuzumab primary sclerosing cholangitis (PSC) study was associated with significantly reduced rate of PSC-related events. p values by Fisher’s exact testBack to article page